Hypertrophy and dietary tyrosine ameliorate the phenotypes of a mouse model of severe nemaline myopathy

Brain

Volumn 134, Issue 12, 2011, Pages 3513-3526

  Nguyen, Mai Anh T ^a,b   Joya, Josephine E ^a   Kee, Anthony J ^a   Domazetovska, Ana ^c,d   Yang, Nan ^c,d   Hook, Jeff W ^a   Lemckert, Frances A ^c   Kettle, Emma ^b   Valova, Valentina A ^b   Robinson, Philip J ^b   North, Kathryn N ^c,d   Gunning, Peter W ^a,c   Mitchell, Christina A ^e   Hardeman, Edna C ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

animal models; nemaline myopathy; treatments; tyrosine

Indexed keywords

SOMATOMEDIN C; SYNAPSIN I; TYROSINE;

ANIMAL MODEL; CONFERENCE PAPER; DIET SUPPLEMENTATION; DISEASE SEVERITY; FOREARM; GENE FREQUENCY; GENE TARGETING; JOINT MOBILITY; LIFESPAN; MOUSE; MUSCLE ATROPHY; MUSCLE STRENGTH; MUSCLE WEAKNESS; NEMALINE MYOPATHY; NONHUMAN; PRIORITY JOURNAL;

EID: 83755220659     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr274     Document Type: Conference Paper

References (63)

1. Acworth IN, During MJ, Wurtman RJ. Tyrosine: effects on catecholamine release. Brain Res Bull 1988; 21: 473-7. (Pubitemid 19269164)
2. Andersson DR, Nissbrandt H, Bergquist F. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur J Neurosci 2006; 24: 617-24. (Pubitemid 44100353)
3. Avraham Y, Bonne O, Berry EM. Behavioral and neurochemical alterations caused by diet restriction -the effect of tyrosine administration in mice. Brain Res 1996; 732: 133-44. (Pubitemid 26305298)
4. Avraham Y, Hao S, Mendelson S, Berry EM. Tyrosine improves appetite, cognition, and exercise tolerance in activity anorexia. Med Sci Sports Exerc 2001a; 33: 2104-10. (Pubitemid 33126705)
5. Avraham Y, Hao S, Mendelson S, Bonne O, Berry EM. Diet restriction in mice causes a decrease in hippocampal choline uptake and muscarinic receptors that is restored by administration of tyrosine: interaction between cholinergic and adrenergic receptors influencing cognitive function. Nutr Neurosci 2001b; 4: 153-67. (Pubitemid 34071735)
6. Barohn RJ, Jackson CE, Kagan-Hallet KS. Neonatal nemaline myopathy with abundant intranuclear rods. Neuromuscul Disord 1994; 4: 513-20. (Pubitemid 24331540)
7. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002; 157: 137-48.
8. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420: 418-21. (Pubitemid 35415652)
9. Bruusgaard JC, Brack AS, Hughes SM, Gundersen K. Muscle hypertrophy induced by the Ski protein: cyto-architecture and ultrastructure. Acta Physiol Scand 2005; 158: 141-9. (Pubitemid 41392357)
10. Campbell WW, Leidy HJ. Dietary protein and resistance training effects on muscle and body composition in older persons. J Am Coll Nutr 2007; 26: 696S-703S.
11. Chang AC, Hook J, Lemckert FA, McDonald MM, Nguyen MA, Hardeman EC, et al. The murine stanniocalcin 2 gene is a negative regulator of postnatal growth. Endocrinology 2008; 149: 2403-10. (Pubitemid 351574495)
12. Charge SBP, Brack AS, Hughes SM. Aging-related satellite cell differentiation defect occurs prematurely after Ski-induced muscle hypertrophy. Am J Physiol Cell Physiol 2002; 283: C1228-41.
13. Corbett MA, Robinson CS, Dunglison GF, Yang N, Joya JE, Stewart AW, et al. A mutation in α-tropomyosinslow affects muscle strength, maturation and hypertrophy in a mouse model for nemaline myopathy. Hum Mol Genet 2001; 10: 317-28. (Pubitemid 32166543)
14. Cowling BS, McGrath MJ, Nguyen MT, Cottle DL, Kee AL, Brown S, et al. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J Cell Biol 2008; 183: 1033-48.
15. Crowe MJ, Weatherson JN, Bowden BF. Effects of dietary leucine supplementation on exercise performance. Eur J Appl Physiol 2006; 97: 664-72. (Pubitemid 44144999)
16. Dupler TL, Cortes C. Effects of a whole-body resistive training regimen in the elderly. Gerontology 1993; 39: 314-9. (Pubitemid 24024644)
17. During MJ, Acworth IN, Wurtman RJ. Dopamine release in rat striatum: physiological coupling to tyrosine supply. J Neurochem 1989; 52: 1449-54. (Pubitemid 19109494)
18. Gregorevic P, Plant DR, Leeding KS, Bach LA, Lynch GS. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am J Pathol 2002; 161: 2263-72. (Pubitemid 35434870)
19. Growdon JH, Melamed E, Logue M, Hefti F, Wurtman RJ. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life Sci 1982; 30: 827-32. (Pubitemid 12105519)
20. Ilkovski B, Clement S, Sewry C, North KN, Cooper ST. Defining α-skeletal and α-cardiac actin expression in human heart and skeletal muscle explains the absence of cardiac involvement in ACTA1 nemaline myopathy. Neuromusc Disord 2005; 15: 829-5. (Pubitemid 41713137)
21. Ilkovski B, Cooper ST, Nowak K, Ryan MM, Yang N, Schnell C, et al. Nemaline myopathy caused by mutations in the muscle alpha-skeletal-actin gene. Am J Hum Genet 2001; 68: 1333-43. (Pubitemid 32510609)
22. Jordan LM, Liu J, Hedlund PB, Akay T, Pearson KG. Descending command systems for the initiation of locomotion in mammals. Brain Res Rev 2008; 57: 183-91. (Pubitemid 350213101)
23. Joya JE, Kee AJ, Nair-Shalliker V, Ghoddusi M, Nguyen M-AT, Luther P, et al. Muscle weakness in a mouse model of nemaline myopathy can be reversed with exercise and reveals a novel myofibre repair mechanism. Hum Mol Genet 2004; 13: 2633-45. (Pubitemid 39485412)
24. Kalita D. A new treatment for congenital nonprogressive nemaline myopathy. J Orthomol 1989; 2: 70-4. (Pubitemid 19152571)
25. Kalsner LR, Rohr FJ, Strauss KA, Korson MS, Levy HL. Tyrosine supplementation in phenylketonuria: diurnal blood tyrosine levels and presumptive brain influx of tyrosine and other large neutral amino acids. J Pediatr 2001; 139: 421-7. (Pubitemid 32889520)
26. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996; 67: 443-62. (Pubitemid 26255637)
27. Laing NG, Wilton SD, Akkari PA, Dorosz S, Boundy K, Kneebone C, et al. A mutation in the α-tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy NEM1. Nat Genet 1995; 9: 75-9.
28. Lindeman E, Spaans F, Reulen J, Leffers P, Drukker J. Progressive resistance training in neuromuscular patients. Effects on force and surface EMG. J Electromyogr Kinesiol 1999; 9: 379-84. (Pubitemid 29505242)
29. Lykkelund C, Nielsen JB, Lou HC, Rasmussen V, Gerdes AM, Christensen E, et al. Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine. Eur J Pediatr 1988; 148: 238-45. (Pubitemid 19016146)
30. Mazzocco MM, Yannicelli S, Nord AM, van Doorninck W, Davidson-Mundt AJ, Greene CL. Cognition and tyrosine supplementation among school-aged children with phenylketonuria. Am J Dis Child 1992; 146: 1261-4.
31. Michel RN, Dunn SE, Chin ER. Calcineurin and skeletal muscle growth. Proc Nutr Soc 2004; 63: 341-9. (Pubitemid 38787488)
32. Molinoff PB, Axelrod J. Biochemistry of catecholamines. Ann Rev Biochem 1971; 40: 465-500.
33. Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007; 11: 113-33. (Pubitemid 46330853)
34. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, et al. Localized IGF-I transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27: 195-200. (Pubitemid 32157448)
35. Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 1964; 239: 2910-7.
36. Nair-Shalliker V, Kee AJ, Joya JE, Lucas CA, Hoh JF, Hardeman EC. Myofibre adaptational response to exercise in a mouse model of nemaline myopathy. Muscle Nerve 2004; 30: 470-80. (Pubitemid 39288151)
37. Nguyen MT, Hardeman EC. Mouse models for thin filament disease. Adv Exp Med Biol 2008; 642: 66-77.
38. Nielsen JB, Lou HC, Andresen J. Biochemical and clinical effects of tyrosine and tryptophan in the Rett syndrome. Brain Dev 1990; 12: 143-7. (Pubitemid 20119247)
39. Nishii K, Matsushita N, Sawada H, Sano H, Noda Y, Mamiya T, et al. Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission. J Neurosci Res 1998; 54: 450-64. (Pubitemid 28507024)
40. North KN, Laing NG, Wallgren-Pettersson C. Nemaline myopathy: current concepts. The ENMC International Consortium and Nemaline Myopathy. J Med Genet 1997; 34: 705-13.
41. Nowak KJ, Wattanasirichaigoon D, Goebel HH, Wilce M, Pelin K, Donner K, et al. Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet 1999; 23: 208-12. (Pubitemid 29455395)
42. Parsons SA, Millay DP, Sargent MA, McNally EM, Molkentin JD. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 2006; 168: 1975-85. (Pubitemid 43825317)
43. Pietz J, Landwehr R, Kutscha A, Schmidt H, de Sonneville L, Trefz FK. Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. J Pediatr 1995; 127: 936-43. (Pubitemid 26004593)
44. Ravenscroft G, Jackaman C, Bringans S, Papadimitriou JM, Griffiths LM, McNamara E, et al. Mouse models of dominant ACTA1 disease recapitulate human disease and provide insight into therapies. Brain 2011; 134: 1101-15.
45. Rifai Z, Kazee AM, Kamp C, Griggs RC. Intranuclear rods in severe congenital nemaline myopathy. Neurology 1993; 43: 2372-7. (Pubitemid 23346980)
46. Ryan MM, Schnell C, Strickland CD, Shield LK, Morgan G, Iannaccone ST, et al. Nemaline myopathy: A clinical study of 143 cases. Ann Neurol 2001; 50: 312-20. (Pubitemid 32848733)
47. Ryan MM, Sy C, Rudge S, Ellaway C, Ketteridge D, Roddick LG, et al. Dietary L-tyrosine supplementation in nemaline myopathy. J Child Neurol 2008; 23: 609-13. (Pubitemid 351715905)
48. Sanoudou D, Beggs AH. Clinical and genetic heterogeneity in nemaline myopathy-a disease of skeletal muscle thin filaments. Trends Mol Med 2001; 7: 362-8. (Pubitemid 32735022)
49. Sanoudou D, Corbett MA, Han M, Ghoddusi M, Nguyen MA, Vlahovich N, et al. Skeletal muscle repair in a mouse model of nemaline myopathy. Hum Mol Genet 2006; 15: 2603-12. (Pubitemid 44288689)
50. Sanoudou D, Haslett JN, Kho AT, Guo S, Gazda HT, Greenberg SA, et al. Expression profiling reveals altered satellite cell numbers and glycolytic enzyme transcription in nemaline myopathy muscle. Proc Natl Acad Sci USA 2003; 100: 4666-71. (Pubitemid 36457787)
51. Sasaki M, Takeda M, Kobayashi K, Nonaka I. Respiratory failure in nemaline myopathy. Pediatr Neurol 1997; 16: 344-6. (Pubitemid 27329945)
52. Shafiq SA, Dubowitz V, Peterson Hde C, Milhorat AT. Nemaline myopathy: report of a fatal case, with histochemical and electron microscopic studies. Brain 1967; 90: 817-28.
53. Shimomura C, Nonaka I. Nemaline myopathy: comparative muscle histochemistry in the severe neonatal, moderate congenital, and adult-onset forms. Pediatr Neurol 1989; 5: 25-31. (Pubitemid 19074477)
54. Sutrave P, Kelly AM, Hughes SH. ski can cause selective growth of skeletal muscle in transgenic mice. Genes Dev 1990; 4: 1462-72.
55. Tanaka S. Dopamine controls fundamental cognitive operations of multi-target spatial working memory. Neural Netw 2002; 15: 573-82. (Pubitemid 34951144)
56. Thurmond JB, Brown JW. Effect of brain monoamine precursors on stress-induced behavioral and neurochemical changes in aged mice. Brain Res 1984; 296: 93-102. (Pubitemid 14156993)
57. Vandekerckhove J, Bugaisky G, Buckingham M. Simultaneous expression of skeletal muscle and heart actin proteins in various striated muscle tissues and cells. A quantitative determination of the two actin isoforms. J Biol Chem 1986; 261: 1838-43. (Pubitemid 17205023)
58. Vlahovich N, Schevzov G, Nair-Shaliker V, Ilkovski B, Artap ST, Joya JE, et al. Tropomyosin 4 defines novel filaments in skeletal muscle associated with muscle remodelling/regeneration in normal and diseased muscle. Cell Motil Cytoskeleton 2008; 65: 73-85.
59. Volpe P, Damiani E, Margreth A, Pellegrini G, Scarlato G. Fast to slow change of myosin in nemaline myopathy: electrophoretic and immunologic evidence. Neurology 1982; 32: 37-41. (Pubitemid 12205262)
60. Wallgren-Pettersson C. Congenital nemaline myopathy. A clinical follow-up of twelve patients. J Neurol Sci 1989; 89: 1-14. (Pubitemid 19029970)
61. Wallgren-Pettersson C, Laing NG. 109th ENMC International Workshop: 5th workshop on nemaline myopathy, 11th-13th October 2002, Naarden, The Netherlands. Neuromuscul Disord 2003; 13: 501-7. (Pubitemid 36937127)
62. Wallgren-Pettersson C, Pelin K, Hilpela P, Donner K, Porfirio B, Graziano C, et al. Clinical and genetic heterogeneity in autosomal recessive nemaline myopathy. Neuromuscul Disord 1999; 9: 564-72. (Pubitemid 29525540)
63. Wallgren-Pettersson C, Rapola J, Donner M. Pathology of congenital nemaline myopathy. A follow-up study. J Neurol Sci 1988; 83: 243-57. (Pubitemid 18043016)